Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Potential Drugs in COVID-19 Management

In Press, (this is not the final "Version of Record"). Available online 15 August, 2023
Author(s): Amin Gasmi, Sadaf Noor, Alain Menzel, Nataliia Khanyk, Yuliya Semenova, Roman Lysiuk, Nataliya Beley, Liliia Bolibrukh, Asma Gasmi Benahmed, Olha Storchylo and Geir Bjørklund*
Published on: 15 August, 2023

DOI: 10.2174/0929867331666230717154101

Price: $95

Abstract

The SARS-CoV-2 virus first emerged in China in December 2019 and quickly spread worldwide. Despite the absence of a vaccination or authorized drug specifically developed to combat this infection, certain medications recommended for other diseases have shown potential effectiveness in treating COVID-19, although without definitive confirmation. This review aims to evaluate the existing literature on the efficacy of these medications against COVID-19. The review encompasses various potential treatments, including antiviral medications, anti-malaria and anti-rheumatic drugs, vaccines, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), antipyretic and analgesic medicines, antiparasitic drugs, and statins. The analysis also addresses the potential benefits and drawbacks of these medications, as well as their effects on hypertension and diabetes. Although these therapies hold promise against COVID-19, further research, including suitable product production or clinical testing, is needed to establish their therapeutic efficacy.

Keywords: Coronavirus, COVID-19, antivirals, antibiotics, hypertension, hyperglycemia, statins, pandemic.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy